Comparative Study of Prednisolone and Cerebrolysin Treatments for Bell's Palsy

What this Trial Is About

Bell's palsy is a common facial nerve disorder causing weakness or paralysis on one side of the face. This research evaluates the effects of two treatments, Prednisolone and Cerebrolysin, to study how well Cerebrolysin helps nerve regeneration compared to corticosteroids. The trial is a randomized, double-blind study sponsored by October 6 University, focusing on adults aged 18 to 60 years with acute unilateral facial palsy of unknown cause. Participants will be assigned to one of three treatment groups: Prednisolone alone, Cerebrolysin alone, or a combination of both. Prednisolone is given as a 60 mg tablet once daily for 5 days followed by a tapering dose, while Cerebrolysin is administered intramuscularly at 10 mg daily for 3 weeks. The study monitors changes in facial nerve function over three weeks using standardized grading systems. During the study, participants will be assessed at baseline, after 1 week, and after 3 weeks using the House-Brackmann and Sunnybrook grading scales to measure facial nerve recovery. Researchers will track progress and safety throughout the trial period. Total participation time includes initial screening and treatment phases, with follow-up evaluations to measure treatment outcomes and monitor for any complications.

Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy